FRA
CNMD icon

Front Row Advisors’s CONMED CNMD Stock Holding History

Front Row Advisors’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37
Closed -$4K – 916
2019
Q3 		$4K Sell
37
-53
-59% -$4.98K ﹤0.01% 643
2019
Q2 		$8K Hold
90
– – 0.01% 475
2019
Q1 		$8K Buy
90
+12
+15% +$872 0.01% 479
2018
Q4 		$5K Buy
78
+8
+11% +$547 ﹤0.01% 527
2018
Q3 		$5K Buy
70
+17
+32% +$1.31K ﹤0.01% 549
2018
Q2 		$4K Buy
+53
New +$3.6K ﹤0.01% 655

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Front Row Advisors's CNMD Position: Q4 2019 in Review

Front Row Advisors sold out of CONMED (CNMD) in Q4 2019, closing a stake of 37 shares — an estimated $4K sold.

Front Row Advisors first reported a position in CNMD in Q2 2018 and held it in 6 quarters. The position peaked at $8K in Q2 2019. 264 funds tracked by Wall St. Rank hold CNMD as of Q4 2019.

  • Front Row Advisors reported no remaining CONMED position as of Q4 2019 after selling out during the quarter.
  • Front Row Advisors sold 37 CONMED shares in Q4 2019, an estimated $4K.
  • Front Row Advisors first reported a position in CONMED in Q2 2018 and held it in 6 quarters.
  • Front Row Advisors's CONMED position peaked at $8K in Q2 2019.
  • 264 funds tracked by Wall St. Rank held CONMED as of Q4 2019.

Based on Front Row Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.